NDC 70594-097-01 - Ceftriaxone
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 70594-097
- Requested NDC
- 70594-097-01
- Package NDCs from labels
- 70594-097-01, 70594-097-02
- Manufacturer
- Xellia Pharmaceuticals USA LLC
- Effective date
- 2022-04-07
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Ceftriaxone - Xellia Pharmaceuticals USA LLC | Xellia Pharmaceuticals USA LLC | 2022-04-07 | HUMAN PRESCRIPTION DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 70594-097-02 | 2024-07-30 | C162847 | 48780-1 | 1030e365-1b01-111a-e063-dadaa90a10e2 | CEFTRIAXONE FOR INJECTION, USP (For Intravenous or Intramuscular Use) |
| 70594-097-02 | 2024-01-30 | C162847 | 48780-1 | 1030e365-1b01-111a-e063-dadaa90a10e2 | CEFTRIAXONE FOR INJECTION, USP (For Intravenous or Intramuscular Use) |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 70594-097-01 | Ceftriaxone | 1 in 1 VIAL | INJECTION, POWDER, FOR SOLUTION | 1 | 1 | |
| 70594-097-02 | Ceftriaxone | 25 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 25 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 70594-097-01 | EA - Each | 70594-097 | e0c822a6-986b-4540-8976-0ab135d5ffa7 | 1 | 2022-08-04 |
| 70594-097-02 | EA - Each | 70594-097 | 517ac225-60e3-471e-993b-bace0ca476f8 | 1 | 2022-08-04 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Sportpharm LLC | ddbc3bf6-5bab-4851-ae5a-ef263cd8f255 | 2026-07-23 | Warnings, Adverse reactions | 1665005 309092 1665021 023Z5BR09K |
| Ceftriaxone | CEFTRIAXONE | WG Critical Care, LLC | 86ec0a92-a552-4a6d-9125-a54f95e43392 | 2026-06-18 | Warnings, Adverse reactions | 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Sportpharm LLC | 85ce4f8b-77e0-48bf-9f57-93f1478befa2 | 2026-04-24 | Warnings, Adverse reactions | 1665021 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Sportpharm LLC | 9a937e47-8c36-4656-83e1-b3c18ed9bac3 | 2026-04-24 | Warnings, Adverse reactions | 1665005 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | REMEDYREPACK INC. | 9c801096-ca61-4b29-a1e1-5f7e7813b191 | 2026-02-06 | Warnings, Adverse reactions | 1665021 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Qilu Pharmaceutical Co., Ltd. | 4cdf0743-c62b-4969-b9c9-4c6400644f6c | 2026-02-04 | Warnings, Adverse reactions | 1665046 1665005 309092 1665021 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Hospira, Inc | 128bb292-d174-4769-b3e6-9f16617f31e3 | 2026-01-22 | Warnings, Adverse reactions | 1665046 1665021 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Hospira, Inc | 19141ccd-e66c-49a2-a794-0616028495a7 | 2026-01-19 | Warnings, Adverse reactions | 1665046 1665005 309092 1665021 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Hospira, Inc | 03283208-8616-4117-9d2b-aa8046017a4f | 2026-01-19 | Warnings, Adverse reactions | 1665046 1665005 309092 1665021 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Hospira, Inc | 365fc265-8e6c-432f-9fda-911f5f7fb451 | 2026-01-16 | Warnings, Adverse reactions | 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Hospira, Inc | 36c07ebf-b091-483e-b2c4-f0fc0c2b4186 | 2026-01-16 | Warnings, Adverse reactions | 023Z5BR09K |
| Ceftriaxone | CEFTRIAXONE | WG Critical Care, LLC | 7bed9b33-29e3-4f04-9766-43a21c7ad47a | 2026-01-07 | Warnings, Adverse reactions | 1665046 1665021 023Z5BR09K |
| Ceftriaxone | CEFTRIAXONE | WG Critical Care, LLC | befd73ff-cb3b-4543-8a8e-bdb9b7fc1ff0 | 2025-04-07 | Warnings, Adverse reactions | 1665046 1665005 1665021 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Sandoz Inc | 53df951b-2eee-44b1-bae2-df7ed85bc0ed | 2025-02-28 | Warnings, Adverse reactions | 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Sandoz Inc | de028434-46cf-44f6-8ac6-889c7c6943b3 | 2025-02-27 | Warnings, Adverse reactions | 1665046 1665005 309092 1665021 023Z5BR09K |
| Ceftriaxone | CEFTRIAXONE SODIUM | Baxter Healthcare Company | 4c5c2d3f-5038-41a1-a2fe-4dcd048dbac1 | 2024-10-07 | Warnings, Adverse reactions | 1665046 1665021 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | A-S Medication Solutions | 53415af6-4072-4339-83e2-d870ae02a0e2 | 2024-08-20 | Warnings, Adverse reactions | 1665005 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | A-S Medication Solutions | b642877e-0d36-4218-afe9-0a39f35b571d | 2024-03-27 | Warnings, Adverse reactions | 1665005 023Z5BR09K |
| Ceftriaxone | CEFTRIAXONE | Civica, Inc. | 96f3fc1e-84f4-4e9b-91ac-19a1692f227a | 2024-02-06 | Warnings, Adverse reactions | 1665046 1665021 023Z5BR09K |
| Ceftriaxone Sodium | CEFTRIAXONE SODIUM | Proficient Rx LP | 790279d4-2456-4091-abec-960b78885432 | 2024-02-01 | Warnings, Adverse reactions | 1665005 023Z5BR09K |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.